India-based Zenara Pharma Private Limited, a Biophore company, announced on Thursday that it has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Capsules, 150 mg and 200 mg.
This approval marks the first FDA-approved generic equivalent of the reference listed drug marketed by Almatica Pharma LLC.
The product has also been granted Competitive Generic Therapy (CGT) designation by the FDA. As the first approved applicant under this pathway, Zenara's ANDA has secured 180 days of marketing exclusivity in the United States, which commenced with the product's launch.
Sertraline Hydrochloride Capsules are classified as selective serotonin reuptake inhibitors (SSRIs) and are indicated for the treatment of Major Depressive Disorder (MDD) in adults and obsessive-compulsive disorder (OCD) in adults and paediatric patients aged six years and older.
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Jazz Pharmaceuticals' Modeyso approved by US FDA for H3 K27M-mutant diffuse midline glioma treatment
Freenome and Exact Sciences agree licensing deal for CRC blood test
Intas Pharmaceuticals and Accord BioPharma acquire UDENYCA (pegfilgrastim-cbqv)
FDA approves Teva's AJOVY for paediatric episodic migraine prevention
Galapagos receives FDA RMAT designation for CAR-T therapy in mantle cell lymphoma
Novo Nordisk expands legal action over compounded 'semaglutide'
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
Mabwell's 7MW4911 IND application accepted by regulators in China and US
Novartis' new Leqvio (inclisiran) indication receives FDA approval
Novo Nordisk's Alhemo haemophilia treatment receives expanded US FDA approval
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval